Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia
University of Pittsburgh
15 participants
Mar 1, 2020
INTERVENTIONAL
Conditions
Summary
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Eligibility
Inclusion Criteria7
- Subjects
- African American
- Patients with sickle cell anemia
- years old or older
- Control
- African American healthy controls
- years of age or older
Exclusion Criteria4
- Pregnancy,
- Known hypertension,
- Hemodialysis and active obstructive sleep apnea requiring treatment.
- Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral; 20mg once a day for 14 days
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04109820